Crohn's disease pipeline overview
| Agent | Mechanism of action |
| CCX-025 | Inhibits the chemokine receptor CCR9 |
| CCX282-B | Inhibits the chemokine receptor CCR9 |
| ZP1848 | GLP-2 agonist |
| Laquinimod | Interferes with migratory capacity of T cells and reduces IL-17 levels |
| NN8555 | Anti-NKG2D |
| TASOCITINIB | JAK3 inhibitor |
| Remestemcel-L | Adult stem cells |
| PDA-001 | Human placenta-derived stem cells |
| OvaSave | Type 1 regulatory T cell |
| Adalimumab | Neutralisation of TNFα activity |
| Infliximab | Neutralisation of TNFα activity |
| Certolizumab pegol | Neutralisation of TNFα activity |
| Debiaerse | TNFα inhibitor, TNFα kinoid |
| HMPL-004 | Chinese herb extract |
| Ozoralizumab | Neutralisation of TNFα activity |
| Vedolizumab | Blockade of α4β7 integrin |
| Natalizumab | Blockade of α4 subunit of α4β1 and α4β7 integrins |
| PF-547659 | Blockade of human mucosal addressin cell adhesion molecule-1 (MAdCAM) |
| ELND-004 | Blockade of α4β1 integrin |
| AJM-300 | Blockade of α4 integrin |
| Secukinumab (AIN457) | Blockade of IL-17A |
| GSK1070806 | Blockade of IL-18 |
| AMG 824 | Blockade of IL-17R |
| PF 05230900 | IL-21 receptor antagonist |
| PF 04236921 | Blockade of IL-6 |
| QAX576 | IL-13 antagonist therapy |
| Vidofludimus | Inhibitor of IL-17A and IL-17F |
| Ustekinumab | Blockade of IL-12/23 |
| SCH900222 | Blockade of IL-23 (p19) |
| C326 | Inhibitor of IL-6 |
| RER rifaximin | Rifaximin |
| RDP58 | IRAK4/TRAF6/MyD88 signalling |
TNFα, tumor necrosis factor alpha; IL, interleukin; JAK, janus kinase; NF, nuclear factor; CCR9, C-C chemokine receptor type 9; GLP-2, glucagon-like peptide-2; IRAK, interleukin-1 receptor associated kinase; TRAF, TNF receptor associated factor; MyD, myeloid differentiation primary response gene.